Lockheed Martin heads into the final stretch before its July 21 Q2 earnings date with the stock grinding higher, shorts sitting on the sidelines, and the Street carrying a cautiously constructive tone that the current price hasn't quite caught up with yet.
The price action remains steady rather than exciting. Shares closed at $535.95 on Tuesday — up about 1.1% on the week and nearly 4% over the past month — continuing a measured recovery from the sharp April selloff. That April drop left a mark: Q1 earnings on April 23 sent the stock down 7.6% in a single session and it remained lower five days later. The more recent May print reversed the narrative, with shares gaining 1.5% the day after results. The direction of travel is improving, but the memory of April still shapes how the Street is positioned heading into July. Among peers, RTX led the defense complex this week, adding 2.9%, while NOC was broadly flat at +0.5%. DRS bucked the trend, falling 3.7%, suggesting this week's bid was more selective than sector-wide.
The short-selling picture remains about as benign as it gets for a stock of this size. Short interest edged up 5% over the past week to 1.1% of the free float — a low reading in absolute terms, though it has climbed roughly 14% over the past month. That monthly drift is worth watching, but the absolute level still doesn't point to meaningful bear conviction. The lending market offers no friction whatsoever: availability is essentially uncapped, with over 137 million shares available to borrow. Borrowing cost ticked up about 9% on the week to 0.45% — noisy but negligible. Options positioning is equally calm. The put/call ratio is running at 0.58, barely above its 20-day average of 0.57 and well within normal range. The 52-week high on the PCR is 0.86, which puts the current reading near the low end of the annual spectrum — options traders are not hedging aggressively.
The Street holds a different view of value than the market does right now. The analyst consensus price target averages $625 — roughly 17% above the current price — though the direction of recent moves has been lower rather than higher. Citigroup cut its target to $571 in mid-May while holding a Neutral rating. Morgan Stanley and RBC both trimmed targets after the April earnings miss, landing at $653 and $575 respectively. No firm has upgraded the stock since the April shock. The result is a consensus that points to meaningful upside but lacks fresh catalysts to pull the price there. Valuation multiples have nudged higher: the P/E has climbed to 17.4x, up from just under 17.2x a month ago, and EV/EBITDA has firmed above 12.3x. Neither reads as expensive relative to the group. The dividend score ranks in the 97th percentile of the universe, underscoring why income-focused buyers remain a bedrock holder base — State Street and BlackRock together hold more than 21% of shares outstanding.
The bull case rests on the Missiles and Fire Control segment, where revenue grew more than 10% year-on-year, and on the resilience of Space and F-35 programmes. The bear case is harder to dismiss: full-year free cash flow guidance was cut to roughly $6 billion, and the April quarter showed significant programme losses across multiple segments, including a dramatic margin collapse in Aeronautics. The ORTEX short score has edged up modestly to 29.4, its highest level of the past two weeks, but remains far below levels that signal structural short pressure. The setup is more about whether the Q2 print on July 21 can rehabilitate execution credibility than about any near-term short-side squeeze or positioning unwind.
What to watch: whether the slow monthly drift higher in short interest continues through July, and whether any of the Neutral-rated analysts — particularly Citigroup, which holds the most recently adjusted target — revisit their stance after the Q2 results land.
See the live data behind this article on ORTEX.
Open LMT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
